行情

CLRB

CLRB

Cellectar
NASDAQ

实时行情|Nasdaq Last Sale

2.430
-0.010
0.00%
盘后: 2.340 -0.09 -3.70% 18:53 09/20 EDT
开盘
2.420
昨收
2.430
最高
2.500
最低
2.410
成交量
8.94万
成交额
--
52周最高
4.280
52周最低
1.220
市值
2,283.24万
市盈率(TTM)
-0.6753
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CLRB 新闻

  • Key events next week - healthcare
  • Seeking Alpha - Article.1天前
  • Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference
  • GlobeNewswire.2天前
  • Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
  • GlobeNewswire.5天前
  • 35 Stocks Moving In Friday's Mid-Day Session
  • Benzinga.09/13 16:56

更多

所属板块

制药
+1.04%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

CLRB 简况

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
展开

Webull提供Cellectar Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。